Background-Sugar-sweetened beverage consumption is associated with weight gain and risk of type 2 diabetes mellitus.
C onsumption of sugar-sweetened beverages has repeatedly been associated with weight gain and type 2 diabetes mellitus (T2D). [1] [2] [3] However, few studies have investigated the relationship between sugar-sweetened beverage intake and incident cardiovascular disease (CVD). Such a relationship might be expected, given their association with adiposity and T2D. In an analysis of the Nurses' Health Study, sugar-sweetened beverage intake was associated with incident coronary heart disease (CHD) even after adjustment for these factors, 4 which suggests that other mechanisms are involved.
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Although artificially sweetened beverages such as diet soda have been suggested as alternatives, some prospective cohort studies have linked the consumption of these beverages to cardiometabolic dysfunction. [5] [6] [7] In an analysis of the Health Professionals Follow-Up Study, we found strong evidence that such relationships are due to confounding and reverse causality. 8 The primary objective of this study was to further define the association between sugar-sweetened and artificially sweetened beverage intake and CHD in the Health Professionals Follow-Up Study, a large prospective cohort study of men. The secondary objective was to identify a possible mechanism by adjusting for potential mediators of this relationship and measuring crosssectional associations between beverage intake and blood lipids, hemoglobin A 1c , inflammatory factors, and adipokines.
Methods

Subjects
The Health Professionals Follow-up Study is a prospective cohort study that began in 1986 with the recruitment of 51 529 middle-aged (age, 40 -75 years) male dentists, pharmacists, optometrists, osteopath physicians, podiatrists, and veterinarians. Approximately 97% of participants were of white European descent. Questionnaires were mailed to participants at baseline and biennially to assess health and lifestyle traits (94% response rate). The Health Professionals Follow-up Study was approved by the Harvard School of Public Health Institutional Review board, and all participants gave written consent.
Beverage Intake
A semiquantitative food frequency questionnaire was sent to participants every 4 years. The food frequency questionnaire asked participants to report their usual intake (never to Ն6 times per day) of a standard 355-mL (12-oz) serving (1 glass, can, or bottle) of sugar-sweetened (caffeinated colas, caffeine-free colas, other carbonated sugar-sweetened beverages, noncarbonated sugar-sweetened beverages [fruit punches, lemonades, or other fruit drinks]) and artificially sweetened (caffeinated low-calorie beverages and noncarbonated low-calorie beverages) beverages. Frequency of intake was multiplied by the nutrient content for each food item and summed to produce daily intakes of nutrients and energy.
In a validation study, intake of cola was highly correlated (deattenuated for measurement error) with mean intake from two 7-day diet records (0.84 for sugar-sweetened, 0.74 for artificially sweetened). Intake of noncolas had poorer correlations with intake from 7-day diet records (0.55 for carbonated noncolas, 0.40 for fruit punches/lemonades/other fruit drinks). 9
Blood Samples
Between 1993 and 1995, 18 225 participants provided a blood sample. Blood was collected in tubes containing liquid EDTA and returned to the laboratory on ice via an overnight courier, where the samples were frozen in liquid nitrogen. Participants were subjects in nested case-control studies (eg, T2D, CVD, Parkinson disease, prostate cancer, pancreatic cancer, colon cancer) or healthy men who were randomly selected on the basis of their alcohol-consumption patterns for a study on alcohol intake and biomarkers of ischemic heart disease. Nearly 60% of participants fasted for Ͼ9 hours.
Ascertainment of End Points
Incident CHD was defined as nonfatal or fatal myocardial infarction. Participants were asked in a biennial follow-up questionnaire whether they had experienced a myocardial infarction between January 1986 and December 2008. When an event was reported, we asked permission from the participant to obtain medical records for confirmation. Nonfatal myocardial infarction was defined by use of the World Health Organization criteria, which required clinical symptoms and diagnostic changes on ECG or elevated cardiac enzymes. Death ascertainment was performed by searching the National Death Index, 10 by family members' responses to follow-up questionnaires, or by reports from participants' professional organizations. We requested access to medical records, autopsy reports, and death certificates to confirm all suspected deaths caused by myocardial infarction. Fatal myocardial infarction was confirmed by medical records or autopsy reports. Death certificates alone were not considered sufficient to confirm myocardial infarction as the cause of death unless family members or medical records indicated that the participant was diagnosed with coronary artery disease before death but after admission into the study.
Measurement of Biomarkers
Plasma concentrations of total, high-density lipoprotein, and direct low-density lipoprotein cholesterol and triglycerides were measured by standard methods with reagents from Roche Diagnostics (Indianapolis, IN) and Genzyme (Cambridge, MA). 11, 12 Lipoprotein(a) was measured with a turbidimetric assay on the Hitachi 911 analyzer (Roche Diagnostics) using reagents and calibrators from Denka Seiken (Niigata, Japan). This is the only commercial assay not affected by Kringle type 2 repeats. 13 Red blood cell glycohemoglobin (hemoglobin A 1c ) was measured by a temperature-controlled high-performance liquid chromatography method. 14 C-reactive protein (CRP) was measured on the Hitachi 911 analyzer (Roche Diagnostics) with an immunoturbidimetric assay (Denka Seiken). Interleukin-6, tumor necrosis factor receptors 1 and -2 (TNFr1 and TNFr2), intracellular adhesion molecule-1, and vascular cell adhesion molecule-1 were measured by ELISAs (R&D Systems, Minneapolis, MN). Plasma adiponectin and leptin concentrations were measured by competitive radioimmunoassay (Linco Research, St. Charles, MO). Coefficients of variation for most assays were Ͻ10%.
Statistical Analysis
Participants with a history of T2D, CVD (heart attack, stroke, angina, coronary artery bypass graft), and cancer (except nonmelanoma skin cancer) at baseline were excluded. Participants with an implausible energy intake (Ͻ335 or Ͼ1758 MJ/d) were also excluded, leaving 42 883 participants for analysis (see the online-only Data Supplement for a flowchart showing all exclusions).
Person-time was calculated from the return of the baseline questionnaire until December 31, 2008, death, loss to follow-up, or diagnosis of CHD (fatal or nonfatal), whichever occurred first. Cox proportional hazard models with time-varying covariates with age as the time scale were used for all analyses. Cumulative averages of beverage intake and dietary variables were calculated at each time point and were not updated after a diagnosis of cancer or CVD to limit recall bias. Other covariates were updated at each time point. This was compared with a secondary analysis that used only baseline dietary information. For missing data, the last value was carried forward for body mass index (BMI), smoking, and physical activity.
Beverage intake was grouped into fourths (quartiles), and the Wald test (1 df) of the median value in quartiles was used to evaluate linear trends. Models were adjusted for smoking (never, past, current 1-15 cigarettes/d, current Ͼ15 cigarettes/d, missing), physical activity (quintiles of metabolic equivalents per week, missing), alcohol intake (abstainers, 0 -9.9 g/d, 10 -20 g/d, Ͼ20 g/d, missing), multivitamin use, family history of CHD, pre-enrollment (1981-1986) weight gain (0, 0.9 -1.8, 2.3-4.1, 4.5-6.4, 6.8 -8.6, 9.1-13.2, or Ն13.6 kg) or weight loss (0, 0.9-1.8, 2.3-4.1, 4.5-6.4, or Ն6.8 kg), adherence to a low-calorie diet (1992), total energy intake (quintiles), and BMI (Ͻ23, 23-23.9, 24-24.9, 25-26.9, 27-28.9, 29-30.9, 31-32.9, 33-34.9, Ͼ35 kg/m 2 , missing). Smoking status was missing in 3.9% of participants, whereas physical activity was missing in 0.5% and BMI in 2.2% of participants.
We also adjusted for the alternative Healthy Eating Index (quintiles) 15 to help rule out confounding by other dietary factors. The alternative Healthy Eating Index ranks participants according to their adherence to a healthy dietary pattern, awarding points for higher intakes of fruit, vegetables, nuts/soy, cereal fiber (fiber from cereals, eg, wheat) polyunsaturated:saturated fat, white:red meat; moderate alcohol intake, daily multivitamin use, and low intakes of trans fat. Potential mediators (updated values for self-reported high cholesterol, high triglycerides, high blood pressure, and a past confirmed diagnosis of T2D) were adjusted for in a separate model.
We tested for nonlinear associations using cubic splines (5 knots), and in a sensitivity analysis, we excluded CHD cases occurring during the first 4 years of follow-up. This was done to evaluate the influence of subclinical disease on associations. We also performed an 8-year latency analysis in which diet was updated only after 8 years to determine the role of elapsed time between the assessment of beverage intake and CHD.
Analyses were stratified by age (Ն65 versus Ͻ65 years), smoking (ever versus never), alcohol consumption (drinker versus abstainer), physical activity (low [quintiles 1 and 2], medium [quintiles 3 and 4], high [quintile 5]), family history of T2D (yes versus no), BMI (Ͻ25, 25-29.9, Ն30 kg/m 2 ), past diagnosis of CHD (yes versus no), selfreported high triglycerides (yes versus no), high cholesterol (yes versus no), and high blood pressure (yes versus no). We also stratified for all combinations of mediators (eg, high triglycerides plus T2D versus neither). Interaction tests were performed with the Wald test of cross-product terms (eg, median beverage intake by median BMI in categories).
Cross-sectional associations between cumulatively averaged sugar-and artificially sweetened beverage intake and blood total cholesterol, triglycerides, low-density lipoprotein, high-density lipoprotein, lipoprotein(a), hemoglobin A 1c , CRP, interleukin-6, TNFr1, TNFr2, intracellular adhesion molecule-1, vascular cell adhesion molecule-1, adiponectin, and leptin were examined in 1994 by use of linear regression with a robust variance estimator. As a result of skewed distributions for CRP and interleukin-6, these variables were log transformed. All analyses were adjusted for the case-control study from which blood samples were drawn, and associations were evaluated for differences by fasting state using cross-product terms (fasting by sugar-sweetened beverages). SAS version 9.1 was used for all analyses. A 2-tailed value of PϽ0.05 was considered statistically significant.
Results
Baseline Characteristics
At baseline, participants reported consuming fewer sugarsweetened beverages (2.5 per week, 0.36 per day, SDϭ0.61) than artificially sweetened beverages (3.4 per week, 0.49 per day, SDϭ0.94).
Consumption of sugar-sweetened beverages was associated with several unhealthy lifestyle traits at baseline, including a higher prevalence of current smoking and lower physical activity, but a decreased family history of CHD (Table 1) . It was also associated with a lower overall diet quality (alternative Healthy Eating Index) and intake of cereal fiber, protein, alcohol, and multivitamins but a higher intake of carbohydrate, glycemic load (product of glycemic index [white bread as reference food] and carbohydrate), total fat, trans fat, and energy (Table 1) . Sugarsweetened beverage consumption was associated with higher pre-enrollment weight gain, decreased pre-enrollment weight loss, and a lower adherence to a low-calorie diet (Table 1) . Conversely, artificially sweetened beverage consumption was associated with some healthy lifestyle traits, including a lower prevalence of current smoking and higher physical activity, but a greater family history of CHD (Table 1) . It was also associated with a higher prevalence of high triglycerides, high cholesterol. and high blood pressure (Table 1) . Artificially sweetened beverage consumption was associated with higher overall diet quality (alternative Healthy Eating Index); a lower intake of carbohydrate, cereal fiber, and glycemic load; but a higher intake of protein, total fat, saturated fat, trans fat, and multivitamins. Artificially sweetened beverage intake was also associated with higher pre-enrollment weight gain, pre-enrollment weight loss, adherence to a low-calorie diet, and BMI (Table 1 ).
Cox Regression
There were 3683 incident cases of CHD over 22 years of follow-up (790 852 person-years). Sugar-sweetened beverage Linear regression and logistic regression were used to assess linear trends across quartiles and are significant unless noted (*). †Pre-enrollment (1981-1986) weight gain and weight loss are mutually exclusive. One serving is equivalent to a standard 355-mL (12-oz) can, glass, or bottle.
de Koning et al Sweetened Beverage Intake, CHD Risk, and Biomarkers intake was associated with an increased risk of CHD (top versus bottom quartile, relative riskϭ1.21, 95% confidence interval, 1.10 -1.33; P for trend Ͻ0.01; Table 2 ); however, artificially sweetened beverages were not (relative riskϭ1.04, 95% confidence interval, 0.96 -1.15; P for trendϭ0.05; Table 2 ). Adjustment for smoking, physical activity, alcohol intake, multivitamin use, and family history attenuated the association for sugar-sweetened beverages but strengthened the association for artificially sweetened beverages ( Table 2 ). Further adjustment for pre-enrollment weight change and adherence to a low-calorie diet in 1992 strengthened the association for sugarsweetened beverages but weakened it for artificially sweetened beverages ( Table 2) . Adjustment for dietary factors had the opposite effect, but after adjustment for BMI, the association for artificially sweetened beverages was no longer significant ( Table  2) . Further adjustment for a past diagnosis of T2D, high blood lipids, and high blood pressure only slightly attenuated these associations ( Table 2) . Cubic splines revealed no evidence of nonlinearity in these associations (P for curvature Ͼ0.21).
Using continuous intake yielded similar results (Table 3) . For each additional serving per day, sugar-sweetened beverage consumption was associated with a 19% to 25% increased risk of CHD (PϽ0.02; Table 3 ). Overall, artificially sweetened beverages were not associated with risk of CHD (Pϭ0.05).
Artificially sweetened carbonated noncolas were associated with increased risk; however, their contribution to intake was small.
Repeating this analysis with continuous covariates did not substantially alter the results (data not shown). Associations were similar when baseline beverage intake was used, after the , physical activity (quintiles of metabolic equivalents a week, missing), alcohol intake (categories), multivitamin use, and family history of CHD. Pre-enrollment weight change includes variables for weight gain (categories) and weight loss (categories). The variable for low-calorie diet is for adherence to a low-calorie diet in 1992. Previous T2D refers to any past diagnosis of T2D, whereas high triglycerides, high cholesterol, and high blood pressure are self-reported. elimination of CHD cases in the first 4 years (nϭ272), and in a latency analysis in which diet was updated after 8 years (data not shown). No significant interactions with age, smoking, alcohol, physical activity, family history, BMI, or any mediators or their combinations were observed (data not shown).
Blood Biomarkers
Intake of sugar-sweetened beverages was associated with significantly higher triglycerides, CRP, interleukin-6, TNFr1, and TNFr2 and lower high-density lipoprotein, lipoprotein(a), and leptin (Table 4 ). Associations did not differ significantly according to fasting status (data not shown).
Discussion
In this analysis, consumption of sugar-sweetened but not artificially sweetened beverages was associated with an increased risk of CHD. Sugar-sweetened beverage consumption was associated with some adverse changes in blood lipids, inflammatory factors, and leptin.
Sugar-sweetened beverages provide Ϸ63 MJ per serving 16 and are less satiating than solid foods, [17] [18] [19] which make them important determinants of BMI. In a pooled analysis of the Health Professionals Follow-Up Study and the Nurses Study I and II, an increase in sugar-sweetened beverage intake was associated with a 0.45-kg greater 4-year weight gain in men and women. 3 Conversely, in the PREMIER lifestyle intervention and weight loss trial, a reduced intake of sugar-sweetened beverages was associated with significant weight loss. 20 In trials among overweight children and adolescents, subjects randomized to consume fewer sugar-sweetened beverages lost significantly more weight than participants in control groups. 21, 22 Sugarsweetened beverages also have a high carbohydrate content and glycemic load, which may elevate the risk of T2D 23 and lead to unfavorable changes in blood lipids independently of BMI. In a meta-analysis of 60 trials, replacing dietary fat with carbohydrate increased triglycerides and lowered high-density lipoprotein. 24 A similar effect is attributed to fructose from sugarsweetened beverages, which increases de novo lipogenesis 25 but also the synthesis of uric acid, which may elevate blood pressure. 26 In the PREMIER trial, a reduction in sugarsweetened beverage intake was associated with a significant decrease in systolic and diastolic blood pressures. 27 Finally, advanced glycation end products present in the caramel coloring of colas may play a role as they decrease insulin sensitivity in rodents. 28 In light of this evidence and the fact that in 2004 sugar-sweetened beverages made up Ϸ7% of the total daily energy intake of Americans, 29 sugar-sweetened beverages are important risk factors for CVD.
In this study, consumption of sugar-sweetened beverages was significantly associated with an increased risk of CHD. This was after adjustment for multiple lifestyle-related factors, including overall diet quality and BMI, which were strong risk factors for CHD. We also adjusted for prior weight change and dieting, which could motivate participants to switch from sugarsweetened to artificially sweetened beverages. 30 For a 1-servingper-day increase in sugar-sweetened beverage intake, the risk of CHD increased by 19% (relative riskϭ1.19; 95% confidence interval, 1.11-1.28; PϽ0.01). Similar results were observed in the Nurses' Health Study (nϭ88 520; cases, nϭ3105; follow-up, 24 years) in which a 1-serving-per-day increase in sugarsweetened beverage intake was associated with a 15% increase in risk (relative riskϭ1.15; 95% confidence interval, 1.07-1.20; PϽ0.01). 4 The average baseline intake of sugar-sweetened beverages was slightly higher in the Nurses' Health Study (0.41 servings per day) than in the Health Professionals Follow-Up Study (0.36 servings per day). 4 ; CRP, C-reactive protein; IL-6, interleukin-6; TNFr1, tumor necrosis factor-␣ receptor 1; TNFr2, tumor necrosis factor-␣ receptor 2; VCAM, vascular cell adhesion molecule-1; and ICAM, intracellular adhesion molecule-1. Models are adjusted for the same covariates as in Table 2 except for mediators (high cholesterol, high blood pressure, type 2 diabetes mellitus).
*CRP and IL-6 were log transformed because of highly skewed distributions. Changes in CRP and IL-6 are calculated from parameter estimates representing percent change in the geometric mean (shown). Blood samples were provided in 1994.
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Our results were stable after a number of sensitivity analyses. Using baseline dietary intake did not change the results, and associations were still significant after the exclusion of early cases of CHD, which could be a marker of preexisting disease and a more recent change in beverage intake. Results were essentially the same in an 8-year latency analyses. We found no differences in associations among different strata, including past diagnosis of T2D, self-reported high triglycerides, high cholesterol, high blood pressure, or their combinations.
As in the Nurses' Health Study, 4 we found that the relationship between sugar-sweetened beverage consumption and CHD was not explained by conventional mediators. After adjustment for a past diagnosis of T2D, self-reported high triglycerides, self-reported high cholesterol, and self-reported high blood pressure, the relationship was only slightly attenuated. This suggests that sugar-sweetened beverages may affect CHD risk above and beyond traditional risk factors.
We looked for possible biochemical mediators in our study and found that sugar-sweetened beverage consumption was associated with higher triglycerides and lower high-density lipoprotein. This is consistent with results from a meta-analysis of intervention studies evaluating the replacement of fat with carbohydrate on blood lipids, 24 as well as other trials of fructose intake. 31 We found a slight decrease in lipoprotein(a) with increased consumption of sugar-sweetened beverages; however, the reason for this finding is unclear. Importantly, sugarsweetened beverage consumption was associated with increased levels of several circulating inflammatory factors, including CRP, interleukin-6, TNFr1, and TNFr2. In the Nurses' Health Study, a dietary pattern rich in sugar-sweetened beverages was associated with higher levels of TNFr2, CRP, and interleukin-6. 32 These findings have been validated in a recent trial in which low to moderate intake of sugar-sweetened beverages increased inflammatory factors such as CRP. 33 In this study, fructoseenriched beverages produced the greatest increases in inflammatory factors. 33 Inflammation is a key factor in the pathogenesis of CVD and cardiometabolic disease 34 and could represent an additional pathway by which sugar-sweetened beverages influence risk. Intake of sugar-sweetened beverages could stimulate an inflammatory response through hyperglycemia, which can activate the electron transport chain to produce superoxide radicals. 35 Fructose also stimulates transcription of inflammatory factors by activating nuclear factor-B in mice. 36 Finally, we observed an inverse relationship between sugar-sweetened beverage intake and leptin. Small trials indicate that fructosesupplemented meals lead to poor stimulation of leptin, lower satiety, higher energy intake, and weight gain. 37 We found no evidence to suggest that overall consumption of artificially sweetened beverages was associated with CHD risk or changes in biomarkers; however, noncarbonated artificially sweetened beverages were associated with increased risk in an analysis of continuous intake. The reason for this is unclear, especially because we found no significant associations between artificially sweetened beverages and biomarkers. Previous studies have found significant associations between artificially sweetened beverage consumption, cardiometabolic dysfunction, and T2D [5] [6] [7] ; however, these findings are probably due to confounding and reverse causality. In the Health Professionals Follow-Up Study, participants appear to be consuming artifi-cially sweetened beverages as part of a weight-loss strategy or in response to the diagnosis of a chronic condition. In a previous analysis of this study, sugar-sweetened beverage consumption was associated with an increased risk of T2D, but this was not significant after adjustment for BMI, pre-enrollment weight change, and dieting. 8 We saw a similar pattern of attenuation in the present analysis; however, the magnitude of confounding was smaller. Our results highlight the need for cautious interpretation of studies reporting positive associations between diet drinks and cardiometabolic and cardiovascular outcomes.
Our study has some limitations. First, dietary intakes were measured with some error. Second, participants in our study may be dissimilar to those living in the general population. For example, intake of sugar-sweetened beverages was much lower in our study (mean, 0.36 servings per day) than in US adults (mean, Ͼ1 serving per day). 38 However, the similarity of the sugar-sweetened beverage-CHD relationship across various strata suggests that it is likely to be the same in different populations. Third, we cannot exclude the possibility of unmeasured and residual confounding. To address this issue, we adjusted for a wide range of potential confounders and used continuous covariates in an attempt to control residual confounding. We could not account for residual confounding resulting from missing smoking, physical activity, and BMI data. Fourth, we tested for a large number of cross-sectional associations. However, our results are supported by other studies, which suggests that they are not due to chance.
Conclusions
Consumption of sugar-sweetened but not artificially sweetened beverages was associated with a significantly increased risk of CHD. Sugar-sweetened beverage intake was also associated with adverse changes in some blood lipids, inflammatory factors, and leptin. These results and those from other observational studies and trials support recommendations to reduce the consumption of sugar-sweetened beverages to prevent CVD.
CLINICAL PERSPECTIVE
Consuming sugar-sweetened beverages such as cola puts individuals at an increased risk for weight gain and type 2 diabetes mellitus, both of which are risk factors for coronary heart disease (CHD). However, few studies have assessed the relationship between sugar-sweetened beverage consumption and CHD events. In our analysis of the Health Professionals Follow-Up Study, a prospective cohort study that includes a well-characterized population of Ͼ40 000 men, we found that sugar-sweetened beverage consumption was associated with a higher risk of CHD independently of body mass index, type 2 diabetes mellitus, and other established cardiovascular risk factors. For each additional serving per day, sugar-sweetened beverages were associated with a 19% increased risk of CHD. We also found that sugar-sweetened beverage consumption was associated with adverse changes in blood lipids, higher circulating inflammatory factors, and lower leptin. These biomarker changes may help to explain why sugar-sweetened beverage consumption is a risk factor for CHD and, in the case of leptin, obesity. Conversely, consumption of artificially sweetened beverages such as diet soda was not associated with CHD risk or biomarkers in our study but was associated with baseline comorbidities, higher body mass index, pre-enrollment weight change, and dieting, which could lead to confounding. 
